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Abstract
Background: Recent declines in invasive breast cancer have been reported in the US, with many studies linking these 
declines to reductions in the use of combination estrogen/progestin hormone therapy (EPHT). We evaluated the 
changing use of postmenopausal hormone therapy, mammography screening rates, and the decline in breast cancer 
incidence specifically for Marin County, California, a population with historically elevated breast cancer incidence rates.
Methods: The Marin Women's Study (MWS) is a community-based, prospective cohort study launched in 2006 to 
monitor changes in breast cancer, breast density, and personal and biologic risk factors among women living in Marin 
County. The MWS enrolled 1,833 women following routine screening mammography between October 2006 and July 
2007. Participants completed a self-administered questionnaire that included items regarding historical hormone 
therapy regimen (estrogen only, progesterone only, EPHT), age of first and last use, total years of use, and reason(s) for 
stopping, as well as information regarding complementary hormone use. Questionnaire items were analyzed for 1,083 
non-Hispanic white participants ages 50 and over. Breast cancer incidence rates were assessed overall and by tumor 
histology and estrogen receptor (ER) status for the years 1990-2007 using data from the Northern California 
Surveillance, Epidemiology and End Results (SEER) cancer registry.
Results: Prevalence of EPHT use among non-Hispanic white women ages 50 and over declined sharply from 21.2% in 
1998 to 6.7% by 2006-07. Estrogen only use declined from 26.9% in 1998 to 22.4% by 2006-07. Invasive breast cancer 
incidence rates declined 33.4% between 2001 and 2004, with drops most pronounced for ER+ cancers. These rate 
reductions corresponded to declines of about 50 cases per year, consistent with population attributable fraction 
estimates for EPHT-related breast cancer. Self-reported screening mammography rates did not change during this 
period. Use of alternative or complementary agents did not differ significantly between ever and never hormone users. 
Of women who reported stopping EPHT in the past 5 years, 60% cited "health risks" or "news reports" as their primary 
reasons for quitting.
Conclusion: A dramatic reduction in EPHT use was followed temporally by a significant reduction in invasive and ER+ 
breast cancer rates among women living in Marin County, California.
Background
The incidence of invasive breast cancer among non-His-
panic white women declined in the early part of this
decade after a long period of increase [1-7]. Investigators
surmised that the decrease could be due to one or more
of several factors: decreases in use of combination estro-
gen-progestin menopausal hormone therapy (EPHT),
treatment of in situ cancers, and saturation or decline in
mammography screening. Although changes in mam-
mography utilization could account for some of the
decrease in incidence at the population level, sharp
declines have been noted among populations subjected to
uniform mammographic screening, indicating that the
decline at the population level is unlikely to be due
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entirely to a change in mammography and is more likely
to be explained by declines in EPHT utilization [8].
Large-scale reductions in utilization of EPHT are thought
to have occurred after reports of negative health effects of
EPHT from the Heart and Estrogen/Progestin Replace-
ment Study (HERS) [9] and Women's Health Initiative
(WHI) [10].
Marin County, California has received media and
research attention due to high breast cancer rates in the
mid- to late- 1990s. Earlier reports indicated that Marin
County's incidence rates were 28% higher than other San
Francisco Bay Area counties and 38% higher than other
urban California counties combined [11]. In a case-con-
trol study of breast cancers conducted in 1997-99 in
Marin County, Wrensch et al. [12] found no difference in
ever use of EPHT in breast cancer cases compared to
controls (35.4% vs. 36%, respectively). After the excess
breast cancer incidence in Marin County was shown to
be due to a disproportionate increase in estrogen recep-
tor (ER)-positive breast cancers [13], a subsequent analy-
sis of the same case-control study revealed that the excess
of ER-positive breast cancers could, in part, be related to
EPHT [14]. A recent assessment of EPHT usage in 2001
in 41 California counties utilizing data from the Califor-
nia Health Interview Survey (CHIS) [15], showed that
Marin County ranked fourth among California counties
with respect to EPHT use prevalence (estimated at 20.4%
of all non-Hispanic white women aged 40-79), while
overall hormone therapy use in Marin women was not
higher than average usage in California. In light of the
recent attention to changes in breast cancer and EPHT
use, this report summarizes recent trends in breast can-
cer incidence, mammography screening rates, as well as
in hormone therapy use and patterns of discontinuation,
in Marin County.
Methods
Marin Women's Study
We used data from the Marin Women's Study (MWS), an
ongoing prospective cohort study of women in Marin
County funded by the CDC to examine breast cancer,
breast density, and associated personal and biologic risk
factors. The MWS was initiated in 2006 and is approved
by the Marin General Hospital IRB. Women with Marin
County residences are recruited at mammogram visits at
each of six mammography centers in Marin County and
at two hospitals in San Francisco that have substantial
attendance from Marin County residents. Women sched-
uled to receive a mammogram are mailed, and asked to
return, an enrollment packet (invitation letter, informed
consent and releases, and scannable questionnaire). The
packet is included with pre-registration materials
required by the mammography clinic, but participation in
the MWS is voluntary. Approximately 31% of the total
population of Marin women are currently participating in
the study.
An 87-item questionnaire was developed for use in the
MWS, and assesses known and suspected breast cancer
risk factors, using validated items where possible. The
draft questionnaire was finalized in an iterative fashion
such that initial items were pretested for acceptance and
understanding in groups of 5-10 women, revised based
on pretest results, pretested in another set of individuals,
and revised again until the pretest results indicated no
further revision was necessary.
Study Population for Current Analysis
The current analysis is a retrospective examination of
prior hormone use using a study population drawn from
the MWS cohort. For this analysis, we included 1,833
women who attended mammography screening at Marin
General Hospital, one of the larger participating clinics,
between October 2006 and July 2007. Women were
excluded if their mammogram was not a routine screen-
ing mammogram (n = 68), were younger than age 50 (n =
494), were missing data on age (n = 17), or were not non-
Hispanic white race (n = 171) leaving an analysis popula-
tion of 1,083.
Breast Cancer Risk Factor Data
Menopausal Hormone Therapy
Women were asked to provide detailed information
about their historical use of estrogen without progester-
one (pills/patches alone, vaginal estrogen, and estrogen
shots) and progesterone without estrogen (creams and
pills/patches). Respondents were asked "Have you ever
used prescription hormone replacement therapy (HRT)
for symptoms of menopause or for other reasons?" To
ascertain type of estrogen used, additional follow-up
questions were asked, and included: "Have you ever used
estrogen pills or patch alone (such as Premarin)?" "Have
you ever used vaginal estrogen?" "Have you ever used
estrogen shots?" "Have you ever used progestin cream?"
"Have you ever used progestin pills or patch alone?" For
each type of estrogen or progestin only regimen, women
were asked the age when treatment was started and
stopped and the total number of years the regimen was
used.
In addition, women were asked about their current and
past use of EPHT regimens. Women were asked "Have
you ever used combination estrogen and progestin (such
as Prempro, Premphase, or Premarin with Progestin)?"
For each regimen, women were asked to indicate the type
of estrogen and number of days a month they used estro-
gen, the type of progestin and the number of days they
used progestin, their age when the regimen was started
and stopped, the total number of years taken and the rea-
son the regimen was discontinued (when applicable).Ereman et al. BMC Public Health 2010, 10:228
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Women were asked to document their most recent, or
current regimen first. Response boxes were also provided
for women to provide the same information on two previ-
ous regimens, if applicable.
Complementary and Alternative Medicines
Complementary and alternative medicine (CAM) utiliza-
tion was ascertained for current use and use in the past 5
years. Stock at local pharmacies was reviewed to ascer-
tain which CAMs to include as response options on the
survey. Women were specifically queried about their use
of combination herbal remedies (eg. Estroven and Estro-
health), black cohosh, chaste tree or berry, Dong Quai,
phytoestrogen/plant estrogens, soy or soy supplements,
wild yam and other. Women were asked to estimate the
total length of time they used these supplements and the
main reason for using it. Specific questions include: "Dur-
ing the past 5 years, have you used any of the following
natural hormone supplements at least weekly for 3 or
more months in a row?" "Please estimate the total length
o f  t i m e  y o u  h a v e  u s e d  t h e s e  n a t u r a l  h o r m o n e  s u p p l e -
ments." "What was the main reason you used the natural
hormone supplements?"
Based on self-reported start and stop date, yearly prev-
alence was calculated for estrogen therapy, EPHT and
CAMS for single years between 1995 and 2006.
Population Mammography and Hysterectomy Data
Mammography screening and hysterectomy rates for
Marin County were ascertained from the California
Health Interview Survey (CHIS) [16,17], using the CHIS
2001 and 2005 Adult Public Use Files. CHIS is a random-
digit dial telephone survey of households in every county
in California. CHIS covers a wide range of topics, includ-
ing health status, health conditions, health-related behav-
iors, health insurance coverage, and access to and use of
health care services. Respondents were asked: "Have you
EVER had a mammogram?", and if yes, asked "How long
ago did you have your most recent mammogram?", and
"Have you ever had a hysterectomy?"
Cancer Incidence Data
Annual cancer incidence and population data from 1990-
2007 for Marin County and California were obtained
from the Northern California Cancer Center, a part of the
National Cancer Institute's Surveillance, Epidemiology,
and End Results (SEER) Program. Analyses included new
cases of invasive breast cancer using International Classi-
fication of Diseases - Oncology, 2nd edition, site codes
50.0-50.9 excluding histology codes 9590-9989 among
non-Hispanic white women aged 50 years or older. For
the purposes of this report and consistent with earlier
reports documenting a particular increase in lobular can-
cer for Marin County [13], all invasive breast cancers
were subdivided for stratified analysis into the following
hormonal and histologic groups: estrogen receptor posi-
tive (ER+), estrogen receptor negative (ER-), lobular cases
(ICD-0-3 morphology codes 8520 and 8522) and non-
lobular/ductal cases (all other morphology codes, includ-
ing unknown histology, but primarily consisting of code
8500/ductal histology).
Statistical Analyses
Stata 8 (Stata Corporation) was used for all analyses of
MWS data. Prevalence estimates and their 95% confi-
dence intervals were calculated for each HT regimen for
the current year (i.e., at the time of the survey in 2006/
2007) and for prior years using recalled data. For years
prior to the survey year (2006/2007), prevalence was cal-
culated for women who were aged 50+ in that year (i.e.,
the denominator for each year only included women aged
50+ in that year). Statistical comparisons of the propor-
tion of women using hormone therapy across years were
made by comparing the 95% confidence intervals. A chi-
squared statistic and the associated p-value were used to
compare the reasons for quitting hormone therapy for
those who quit within the past 5 years compared to those
who quit 10 or more years ago. The online tool
"AskCHIS" was used to calculate the prevalence of mam-
mography use in 2001 and 2005 with 95% confidence
intervals, as well as the prevalence of hysterectomy in
2005. SEER*Stat software (version 6.4.4) was used to cal-
culate all age-adjusted and age-specific cancer incidence
rates (age-adjusted to the 2000 US population standard),
associated standard errors and 95% confidence intervals.
Age-adjusted incidence rates were compared statistically
using a Wald chi-square test of the difference between
two rates with p-values of less than 0.05 considered sig-
nificantly different. Use of Joinpoint regression was
explored in preliminary analyses but yearly case counts
were insufficient to detect year to year differences.
Results
Demographic Characteristics
Table 1 describes the demographic characteristics of the
study population compared to estimates for Marin
County as a whole. The average age of the 1,083 non-His-
panic white women included in this analysis was 62.5,
ranging from 50-95, which is similar to Marin overall.
There was broad representation of income groups in this
study population, although compared to Marin as a
whole, a lower percentage of women in the lowest income
and education groups are represented in the MWS study
population. As with the general Marin County popula-
tion, the study population was fairly well educated, with
36.0% having obtained a college degree, and an additional
31.1% having obtained a post-baccalaureate degree. The
majority of the study population was married (63.6%),
with an additional 25.9% being currently single but hav-Ereman et al. BMC Public Health 2010, 10:228
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ing been married in the past. Eighteen percent of the
MWS sample had a hysterectomy, compared to 23.1% of
non-Hispanic white women ages 50+ in Marin [16].
Postmenopausal Hormone Therapy Use
Ever Use
Table 2 shows the various hormone therapy regimens
reported as being used by this study population between
1995 and 2006/2007. The percentage of women ages 50
or older in 2006/2007 who reported ever using EPHT,
EHT only, and/or progestin pill/patch was 56.6% overall,
with 25.3% reporting ever using EPHT, 39.9% reporting
ever use of EHT alone, and 5.9% reporting ever use of a
progestin only pill or patch.
Table 1: Demographic characteristics, non-Hispanic white women ages 50 and over, Marin Women's Study 2006-2007 (n = 
1083) and Marin County as a whole.
n MWS2006-07
%
CHIS 2005-07
%
Age
Mean 62.5 64.5
Range 50-95 50-96
Age Categories
50-59 482 44.5 41.3
60-69 372 34.4 27.8
70-79 158 14.6 18.4
80+ 71 6.6 12.5
Education
H.S or less 62 5.7 17.6
Some college/AA 281 26.0 24.1
BS 390 36.0 35.7
MS 246 22.7 17.5
Doctoral/Professional 91 8.4 5.2
DK/Missing 13 1.2 -
Marital Status
Married 689 63.6 49.9
Widowed/Divorced/
Separated
280 25.9 37.2
Single 68 6.3 8.6
Living Together 44 4.1 4.3
Missing 2 0.2 -
Income
<$75,000 219 20.2 52.3
$75-$150,000 354 32.7 33.4
>$150,000 341 31.5 14.3
Declined/Don't know 169 1.3 -
Missing 2 14.3 -
Ever Hysterectomy
Yes 195 18.0 23.1
No 888 82.0 76.9Ereman et al. BMC Public Health 2010, 10:228
http://www.biomedcentral.com/1471-2458/10/228
Page 5 of 14
Current Use
The proportion of women currently taking prescription
hormone therapy in 2006/2007 in this study population
was 26.0%, with 6.7% of women reporting current EPHT
use, 22.4% reporting EHT only, and 1.9% progestin only.
Trends
Figure 1 illustrates the prevalence of EHT and EPHT uti-
lization among women aged 50 and older from 1995 to
2006. Use of EHT decreased 15.4% over the time period,
though year-to-year decreases were not statistically sig-
nificant. In contrast, use of EPHT changed dramatically
from 1995 to 2006. Overall, a 58.9% reduction was
observed during that time period. The proportion of
women currently using EPHT and the proportion using it
in 2006 were significantly lower than the proportion
using it in every year prior to 2004.
We examined the relative decreases in EPHT use taking
into consideration the publication of the HERS study in
1998 and the WHI trial in 2002. From 1995 to 1998,
EPHT use was steady (0% overall change). Between publi-
cation of the HERS and WHI trials (i.e., 1998 to 2001),
there was a 14% decrease in EPHT use. The largest
decrease occurred after publication of the WHI trial data
in 2002. From 2002 to the time of the survey (2006/2007),
there was a 57.3% drop in EPHT use.
To understand whether overall changes in EPHT use
stemmed from decreases in use for particular age groups,
prevalence of use by age group was calculated for the
years 2001 and 2006 (Table 2). While use in 2006 was
lower than that in 2001 in women 50-59 and 60-69, there
was no evidence of changes in use among women aged 70
years and older.
Initiation and Cessation Behavior
The timing of initiation and cessation of HT is presented
in Table 3. 51.6% of prior EPHT users quit within the past
5 years, which was slightly lower for EHT users (43.8%).
Of current HT users, 47.2% of EPHT users started taking
EPHT within the past 5 years (after WHI and HERS),
compared to 53% of current EHT users.
The reasons prior users reported stopping EPHT are
also shown in Table 3. (These data were not gathered for
EHT use.) The proportion of women who cite quitting
EPHT due to health effects and/or news reports is signifi-
cantly greater among those who quit within the past 5
years than among those who quit 10 or more years ago
(60.0% vs. 29.6%, respectively). The proportion of those
who quit because of a doctor's recommendation was non-
significantly higher among those who quit within the past
5 years compared to those who quit 10 or more years ago
(32.0% vs. 25.9%), while the proportion citing side effects
is significantly lower (11.0% vs. 33.3%, respectively).
Complementary & Alternative Medicines
In this study population, 9.3% of women reported cur-
rently using CAMs for the symptoms of menopause
(Table 4), which is slightly higher than current EPHT
usage (6.7% of women). The prevalence of current use of
C A M s  d i d  n o t  v a r y  b y  h i s t o r y  o f  H T  u t i l i z a t i o n .  S o y
products, black cohosh, and combination herbal reme-
dies were the CAMs most commonly reported as being
currently used (2.5%, 2.3%, and 1.4% of women using,
respectively).
Invasive Breast Cancer Incidence Rates
Figure 2 and Table 5 show annual age-adjusted invasive
breast cancer incidence rates from 1990 to 2007 for non-
Hispanic white women, aged 50 years and older living in
Marin County at the time of diagnosis. Rates reached
their absolute peak of 522.2/100,000 (CI 452.9-599.2) in
1999, an increase of 17% from the beginning of the period
examined (1990). Rates were lowest in 2004, at 345.1
cases/100,000 (CI 291.8-406.3). By the end of the period
examined (2007), the incidence rate in Marin County had
increased to 453.5/100,000 (CI 392.1-522.7), which was
significantly higher than the corresponding rate for the
state of California 379.3/100,000 (CI 372.4-386.2), but
was not significantly higher than the lowest rate for
Marin in 2004.
Figure 3 shows age-specific incidence rates for two time
periods, 1990-2001 and 2004-2007. Although the differ-
ences were not statistically significant, the change in inci-
dence rates appears to be limited to women over the age
of 50 and was greater for the 50-79 year age group than
for women older than 80, although rates were somewhat
unstable for the older age groups.
Breast Cancer Histology and ER Status
The incidence of ER+ tumors in Marin remained rela-
tively constant from 1990 though 2001; ER+ tumors then
dropped sharply and significantly between 2002 and
2004, from 395.3/100,000 to 167.9/100,000 representing a
reduction of over 57% (34.8% a year) or 88 incident cases
(Figure 3). Despite small numbers of cases, there was no
evidence of a significant change in ER- tumor incidence
during that same time period. Case counts, age-adjusted
incidence rates and corresponding confidence intervals
are presented in Table 5.
Figure 2 also shows the incidence trends for invasive
breast cancers according to histologic subtype. Between
1990 and 2007, 70-80% of all breast cancer cases in Marin
County were of ductal/non-lobular histology. Ductal
invasive carcinomas decreased significantly in Marin
County from 362.2/100,000 (CI 303.2-429.6) in 1997 to a
low of 211.8/100,000 (CI 169.7-262.0) in 2003, represent-
ing an 8.6% average annual reduction. Despite small
numbers of cases for analysis, the pattern in lobular
breast cancer incidence differed somewhat from that of
ductal breast cancers. Rates of lobular cancers increased
throughout the 1990s, with the rates in 1999 and 2001Ereman et al. BMC Public Health 2010, 10:228
http://www.biomedcentral.com/1471-2458/10/228
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Table 2: Hormone therapy usage, non-Hispanic white women ages 50 and over, Marin Women's Study 2006/2007 (n = 
1083)
n%
Ever Use -- prescription hormone therapy 613* 56.6
Estrogen Only Ever 432 39.9
Never 625 57.7
Missing 26 2.4
EPHT Ever 274 25.3
Never 809 74.7
Missing 0 0
Progesterone Ever 64 5.9
Pill/Patch Never 1008 93.1
Missing 11 1.0
Ever Use -- prescription hormone therapy by age category
50-59 226 33.0
60-69 291 42.5
70-79 124 18.1
80+ 44 6.4
missing 0 0
Current Use -- prescription hormone therapy 282* 26.0
Estrogen Only No 840 77.6
Yes 243 22.4
Missing 0 0
Type
Pills/Patch No 967 89.3
Yes 110 10.2
Missing 6 0.6
Vaginal Estrogen No 941 86.9
Yes 142 13.1
Missing 0 0
EPHT** No 1010 93.3
Yes 72 6.7
Missing 1 0.1
Progesterone No 1062 98.1
Pill/Patch Yes 20 1.9
Missing 1 0.1
EPHT Use by Age and Year 2001 (%, 95% CI) 2006 (%, 95% CI)
50-59 21.9 (18.2, 25.7) 10.6 (7.8, 13.2)Ereman et al. BMC Public Health 2010, 10:228
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significantly higher than 1991 and 1992. From 2001-2006,
rates decreased somewhat, but these differences did not
reach statistical significance.
Prevalence of Mammography Screening
CHIS survey data suggested consistent trends in self-
reported rates of biannual mammography screening in
Marin County with prevalences of 87.2% (CI 81.7-92.7) in
2001 and 85% (CI 82.8-87.3) in 2005 [16,17]. In Califor-
nia, the prevalences were 82.7% (81.8-83.7) in 2001 and
83.9% (83.0-84.9) in 2005, not significantly different than
the reported screening prevalence in Marin. Differentia-
tion between first and subsequent mammograms could
not be ascertained from this data source.
Discussion and Conclusions
Invasive breast cancer incidence rates in Marin County
among non-Hispanic white women aged 50 years or older
decreased significantly between 2001 and 2004, a reduc-
tion of 33% (7.9% per year). The change in incidence rates
was evident primarily in women ages 50-79. During the
same time period, EPHT utilization dropped more than
50% (9.9% per year) in women 50 and older, and contin-
ued to drop through 2006, while mammography screen-
ing rates remained stable. The reduction in EPHT
utilization preceded the drop in invasive breast cancer
incidence rates, and was seen as early as 1998, with a
more precipitous drop evident between 2001 and 2004.
Early in the investigation of high breast cancer rates in
Marin County, we explored HT use as a possible reason
for the high rates. In the absence of more specific data on
prevalence of EPHT vs. EHT use, we found that overall
HT use in Marin County women ages 50 and over was
not significantly different than the prevalence for the
entire state of California (CHIS 2001). Subsequent analy-
ses using updated data that differentiated between HT
formulations showed that Marin had the 4th highest esti-
mated EPHT prevalence among California counties [15].
60-69 21.2 (15.8, 26.6) 9.7 (6.6, 12.8)
70-79 5.6 (1.2, 10.0) 4.8 (1.3, 8.4)
80+ 0 0
*Does not represent simple sum as regimens are not mutually exclusive
**Estrogen plus progestin hormone therapy
Table 2: Hormone therapy usage, non-Hispanic white women ages 50 and over, Marin Women's Study 2006/2007 (n = 
1083) (Continued)
Figure 1 Trends in combination estrogen plus progestin and estrogen only hormone therapy use among non-Hispanic white women, ages 
50 and over in Marin County 1995-2006.
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One explanation for the high prevalence of EPHT utiliza-
tion in the absence of excess overall HT use is a difference
in the prevalence of hysterectomy. Indeed, further inves-
tigation for this manuscript revealed substantial county
by county variations in hysterectomy rates throughout
California, ranging from 14.9% to 55.8% (San Francisco
and Sutter Counties, respectively) in white women ages
50+, with Marin having the second lowest percentage of
hysterectomies (23.1%) [17]. Understanding why hyster-
ectomies vary so widely geographically, while not the
subject of this manuscript, warrants further investigation.
While our survey did not specifically query women
about HERS and WHI and the resulting press coverage,
we believe that the reduction in HT use is largely attribut-
able to the publication and subsequent dissemination of
these results, as has been documented in other popula-
tions. Interestingly, the proportions of women reporting
physician-initiated cessation of EPHT did not increase in
the post-WHI period (Table 3). This may relate to the
h i g h  e d u c a t i o n a l  s t a t u s  a n d  g o o d  m e d i a  a c c e s s  o f  t h e
study population in question, which may lead women to
discontinue treatment on their own following negative
press on EPHT.
Complementary and alternative hormone (CAM) utili-
zation did not significantly increase despite the fact that
EPHT and EHT use dropped precipitously, suggesting
that women are not replacing prescription hormone ther-
apies with CAMs as a treatment for menopausal symp-
toms. Future research should address whether women are
seeking other therapies to replace EPHT for the treat-
ment of menopausal symptoms, and should address the
relative safety and efficacy of these therapies.
Previous assessments in Marin County women sug-
gested that the excess breast cancer incidence relative to
other urban California geographic areas was predomi-
nantly ER+ lobular and ductal breast cancer cases [13].
Total ER+ Marin breast cancer cases diagnosed between
1997-1998 were associated with excess postmenopausal
hormone therapy use [14]. Larger population studies of
breast cancer subtypes associated with current and long
duration EPHT use have been somewhat contradictory
[18], but in general suggest a link between EPHT use and
Table 3: Initiation and cessation of prescription hormone therapy by regimen, non-Hispanic white women ages 50 and 
over in Marin County, 2006-2007
Regimen Utilization Patterns n %
Estrogen Only (EHT) Past Users who quit within past 5 years 91 43.8 of past users
Ever Users who started in past 5 years 148 34.2
Current users, time started:
≤5 years ago 115 53.0
> 5-10 years ago 47 21.7
> 10 years ago 55 25.4
Estrogen plus 
progestin (EPHT)
Past Users who Quit within past 5 years 100 51.6 of past users
Ever Users who started in past 5 years 53 19.3
Current users, time started:
≤5 years ago 34 47.2
> 5-10 years ago 17 23.6
> 10 years ago 21 29.2
Reasons quit (past users) Quit < 5 yrs ago Quit >10 yrs ago X 2, p-value
n (%) n (%)
Side Effects 11 (11.0) 9 (33.3) 7.99, 0.01
Doctor Recommended 32 (32.0) 7 (25.9) 0.37, 0.54
Health Effects 38 (38.0) 6 (22.2) 2.34, 0.13
News Reports 47 (47.0) 4 (14.8) 9.16, 0.002
Switched types 6 (6.0) 2 (7.4) 0.07, 0.79
Health or News Reports 60 (60.0) 8 (29.6) 7.89, 0.01Ereman et al. BMC Public Health 2010, 10:228
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increased ER+ breast cancer incidence [5,13,18]. In the
present study, the changing incidence of lobular and duc-
tal breast cancer were not concordant with one another
between 1999 and 2003, and changes in total invasive
breast cancer incidence over this period largely reflected
that of the more commonly diagnosed ductal subtype of
breast cancer. Almost all lobular breast cancers and over
60% of ductal breast cancers are ER+; therefore, it is note-
worthy that the change in total ER+ breast cancer inci-
dence rates between 1999 and 2003 not only paralleled
the change in total invasive breast cancer incidence but
showed a precipitous decline after 2001 that better
reflects the change in EPHT use than did the decline in
ductal breast cancer rates. Following the decline in EPHT
use between 2000-2004, ER+ breast cancer incidence
rates dropped by >50% while ductal breast cancer inci-
dence dropped by only 29% and lobular rates showed no
significant change, but the number of lobular cancers is
small making changes in these rates difficult to detect
(Figure 2).
To understand whether the observed reduction in
EPHT therapy was commensurate with the drop in breast
c a n c e r  c a s e s  s e e n  i n  M a r i n  C o u n t y ,  w e  r e f e r r e d  t o  a
recent analysis of the population-level impact of HT on
breast cancer rates which used the population attribut-
able fraction (PAF) to estimate the proportion of breast
cancer incidence rates attributable to EPHT [19]. PAF
estimates were calculated based on a range of EPHT use
(5-22%) and relative risk estimates from the literature
(1.24-3.06) for the risk of EPHT on breast cancer. When
PAF estimates are calculated in the MWS study popula-
tion, using an average prevalence of EPHT use (20%)
from 1999-2001 and moderate relative risk estimates of
1.5 - 2.0, these PAF estimates would suggest that approxi-
mately 22 - 40 cases annually (10-18% of 217 invasive
breast cancer cases per year in 2001-2002 in Marin) could
be attributable to EPHT use in the years before 2002,
commensurate with our observations of 50 fewer cases
per year in Marin County.
The drop in invasive breast cancer incidence in 2002-
2004 was followed by a non-significant increase in inci-
dence rates in 2005-2007. Determining whether this is a
real increase in incidence will only be possible with addi-
tional years' data. The increase may be a statistical aber-
ration given the relatively small number of annual cases
in Marin (and therefore unstable rates), or could be due
to inaccuracies in the population estimates [20]. On the
other hand, if the rate increase proves to be real, it could
be due to replacement of EPHT by another compound
also associated with breast cancer, a rebound emergence
of cases after some delay due to promoting influences
that only temporarily retarded the emergence of new
tumor cases, improved sensitivity of mammography after
removal of EPHT which impeded detection of breast can-
cer [21], or a reflection of downward resetting of the
Marin incidence curve that reveals another underlying
increasing incidence trend that has been happening inde-
pendent of EPHT. It will be important to continue moni-
toring breast cancer incidence rates, the prevalence of
H T  a n d  o t h e r  r i s k  f a c t o r s ,  a s  w e l l  a s  m a m m o g r a p h y
screening changes to determine whether this trend con-
tinues.
Mammography screening rates in Marin County, as
assessed by a statewide population-based survey [16,17],
decreased non-significantly during the study period, sug-
gesting that a large drop-off in mammography utilization
does not explain the breast cancer rate decline in this
population. Similarly, in California, reported screening
rates did not change significantly during this time period
and were not significantly different from those in Marin.
Although overall screening rates did not change signifi-
cantly, a screening saturation effect should also be con-
sidered in assessing changes in incidence rates.
Specifically, the proportion of mammography-detected
cancers that are interval cancers versus existing previ-
ously-undiagnosed cancers will vary depending on the
extent of screening saturation in the population. A
change in the distribution of first to subsequent mammo-
grams (whether cases were detected at first screen, subse-
Table 4: Prevalence of complementary and alternative 
medicine (CAM) usage for menopausal symptoms, non-
Hispanic white women ages 50 and over, Marin County, 
2006-2007 (n = 1083)
n%
Currently Using 101 9.3
Soy Products 27 2.5
Phytoestrogens 8 0.7
Combination Herbal 18 1.4
Black Cohosh 25 2.3
Chaste Tree 6 0.6
Wild Yam 6 0.6
Other 19 1.8
Progestin Cream 21 1.9
Current Users, length of time
<1 year 37 34.6
1 - 2 years 27 25.2
3 - 4 years 19 17.8
5+ years 24 22.4
CAM use in women who have ever used 
hormone therapy
57 9.6
CAM use in women who have never used 
hormone therapy
44 9.0Ereman et al. BMC Public Health 2010, 10:228
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Table 5: Case counts and age adjusted incidence rates: invasive breast cancer, ER+, ER-, ductal and lobular component, 
non-Hispanic white women 50+ Marin County, 1990-2007
Invasive Breast Cancer ER+ ER-
Count Rate 95% C.I. Count Rate 95% C.I. Count Rate 95% C.I.
1990 143 445.4 (374.8 - 526.2) 86 269.6 (215.2 - 334.3) 16 51.3 (29.1 - 84.4)
1991 119 356.1 (294.7 - 427.2) 81 241.2 (191.3 - 300.8) 16 49.3 (28.0 - 81.1)
1992 138 415.3 (348.6 - 491.7) 102 305.5 (248.8 - 371.8) 20 62 (37.7 - 96.5)
1993 166 486.4 (415.0 - 567.1) 115 336.5 (277.6 - 404.6) 23 69.8 (44.2 - 105.2)
1994 150 429.5 (363.3 - 504.6) 108 309.7 (253.9 - 374.5) 18 52.7 (31.2 - 83.8)
1995 160 456.1 (387.9 - 533.0) 118 338.3 (279.8 - 405.6) 17 49.8 (29.0 - 80.0)
1996 184 517.5 (445.2 - 598.5) 144 404 (340.5 - 476.2) 21 59.6 (36.9 - 91.6)
1997 191 516 (445.1 - 595.2) 148 403.7 (341.1 - 474.8) 23 61.8 (39.1 - 93.3)
1998 187 492.7 (424.3 - 569.3) 144 384.1 (323.7 - 452.7) 21 55.1 (34.1 - 84.8)
1999 208 522 (452.9 - 599.2) 157 396.1 (336.1 - 464.2) 29 71.3 (47.6 - 103.5)
2000 188 466 (401.1 - 538.9) 132 335 (279.8 - 398.4) 30 73 (49.0 - 105.3)
2001 210 518 (449.5 - 594.5) 165 410.8 (349.8 - 479.9) 24 58.2 (37.1 - 87.7)
2002 200 484.6 (418.9 - 558.3) 163 395.3 (336.2 - 462.5) 16 39.7 (22.5 - 65.6)
2003 156 365 (309.1 - 428.8) 120 280.1 (231.5 - 336.6) 26 62.3 (40.4 - 92.7)
2004 154 345.1 (291.8 - 406.3) 75 167.9 (131.5 - 212.3) 26 58.7 (38.0 - 87.9)
2005 183 411.7 (353.1 - 478.3) 86 189.4 (151.0 - 235.8) 19 44.6 (26.5 - 71.4)
2006 190 410.7 (353.1 - 476.0) 93 196.1 (157.4 - 242.6) 19 39.9 (23.8 - 64.2)
2007 205 453.5 (392.1 - 522.7) 98 213.7 (172.5 - 262.6) 25 55.1 (35.2 - 83.4)
Ductal Lobular Component
Count Rate 95% C.I. Count Rate 95% C.I.
1990 103 320.8 (261.3 - 390.4) 26 81 (52.7 - 120.0)
1991 97 289.7 (234.6 - 354.5) 9 28.3 (12.9 - 54.7)
1992 89 270.1 (216.7 - 333.3) 17 50.3 (29.2 - 81.5)
1993 98 288.4 (234.0 - 352.2) 32 93.5 (63.9 - 132.8)
1994 92 264.1 (212.7 - 324.5) 34 98.2 (67.9 - 137.7)
1995 102 292.6 (238.4 - 355.7) 41 117.6 (84.3 - 159.9)
1996 116 326.6 (269.7 - 392.2) 34 97.1 (67.1 - 136.1)
1997 134 362.2 (303.2 - 429.6) 32 89.2 (61.0 - 126.3)
1998 128 338.6 (282.3 - 403.2) 37 97.9 (68.8 - 135.5)
1999 124 311.5 (258.7 - 372.5) 54 138.9 (104.1 - 182.2)
2000 136 337.2 (282.4 - 400.1) 25 64.3 (41.4 - 96.0)
2001 116 285.6 (235.5 - 344.0) 60 149.9 (114.0 - 194.2)
2002 116 282.3 (232.6 - 340.1) 47 114 (83.3 - 152.8)
2003 90 211.8 (169.7 - 262.0) 40 90.9 (64.6 - 125.4)
2004 103 233 (189.3 - 284.7) 36 79.3 (55.3 - 111.5)
2005 123 276.7 (229.0 - 332.3) 33 72.2 (49.4 - 103.4)
2006 118 251.7 (207.5 - 303.7) 42 92.7 (66.2 - 127.5)
2007 138 303.8 (254.1 - 361.2) 45 103.5 (74.9 - 140.3)Ereman et al. BMC Public Health 2010, 10:228
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quent screen or not screen detected) and thus a change in
screen-detected cases, has been shown to explain recent
incidence trends outside the U.S. [22,23], but could not be
determined in this study. While screening saturation
prior to 2001 cannot be directly assessed in the Marin
population using these data, one study reporting on
screening patterns in the Western United States [5], indi-
cates that saturation occurred in the late 1980s to early
1990s. It is not likely that Marin deviated substantially
from this pattern. In addition, a recently published manu-
script of a California cohort of women with similar
demographics to Marin found invasive incidence rates
declined significantly in 2003-2005 with consistent levels
of screening throughout the study period [24]. Given the
high prevalence of EPHT utilization and the substantial,
subsequent decline in use in this population, changes in
screen-detected cases would need to be considerable dur-
ing this time period to explain such a dramatic drop in
breast cancer rates in Marin, although the possibility can-
not be discounted. Future research must continue to
monitor mammography utilization patterns alongside
EPHT utilization to examine any association with future
changes in breast cancer incidence rates.
While this interim analysis of the MWS has a number
of strengths, including a large sample size and in-depth
individual-level data on use of EPHT and EHT, as well as
the reasons for stopping EPHT, there are a number of
limitations to this study. The primary limitation is the
possibility of selection bias. We were only able to obtain
information from women currently living in Marin
County, thus excluding women who lived in Marin
County during the retrospective study period but who are
not available for interview due to out-migration or death.
It has been hypothesized that migration of low or high
risk women on the basis of changes in the cost of living
during the 1990's could have affected geographic patterns
in breast cancer incidence [11,25]. Given the association
between EPHT utilization and adverse outcomes, it is
possible that our estimates of EPHT use are lower than
the true prevalences, as current users may have been
more likely to die and thus not be a part of the current
study. In addition, the potential for selection bias is also
present in the form of preferential participation by
women who perceive themselves to be at increased risk of
breast cancer. However, our estimates of the prevalences
of HT utilization in this study are similar to those pub-
lished previously [26], indicating a lack of a strong selec-
tion bias.
HT utilization was assessed in this study in a popula-
tion with uniform access and utilization of mammo-
graphic screening, suggesting a potential source of
selection bias. As expected, given that this is service-
Figure 2 Trends in age-adjusted invasive breast cancer incidence rates, non-Hispanic white women ages 50 and over, Marin County and 
California. ER+, ER-, ductal and lobular component rates Marin County, 1990-2007.
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based population, women with lower SES who have less
access to care are not well represented the MWS study
population. With the exception of the lowest income and
education groups, women in the mammography screen-
ing population are seen as being representative of the
broader population of Marin County women ages 50 and
over, as 70% of women in this age group in Marin report
having a mammogram in the past year [27] and approxi-
mately 90% report having had a mammogram in the past
two years [28]. In addition, the clinic at Marin General
Hospital serves clients with both HMO and PPO insur-
ance plans and has referrals from local community clinics
for the uninsured to receive low- and no-cost mammog-
raphy visits. Efforts continue to include low SES women
in ongoing MWS recruitment. Though the income distri-
b u t i o n  m a y  s e e m  t o  i n d i c a t e  t h a t  o n l y  h i g h  i n c o m e
women are included in the study population, the cost of
living in Marin County is very high, thus, these incomes
represent the range of incomes found in this area.
A second limitation in the current study is the potential
for information bias in the ascertainment of HT utiliza-
tion. HT utilization was based on self-report, rather than
clinical records, and is therefore subject to problems in
recall. Again, we do not see this as a major problem in the
current study as the estimated prevalence of HT use in
2001 in this study population was similar to that found in
two cross-sectional health surveys [16,17] conducted in
Marin County in 2001. In addition, a recent study by
Banks et al. [29], compared medical practice prescription
records to self-reported questionnaire data from women
participating in the Million Women Study and found
excellent agreement between the two.
Another potential source of information bias is in the
calculation of breast cancer incidence rates. Cancer inci-
dence trends can be biased by inaccurate cancer registry
or population projections if the projections or registry
errors change over time. The California Cancer Registry
has produced extremely accurate case counts; case ascer-
tainment was estimated at 99% for 2004 [30]. Intercensal
population projections, on the other hand, can be sub-
stantively incorrect, and have biased breast cancer inci-
dence rate estimation in Marin County in the past decade
[20]. We will not be able to ascertain the extent to which
Figure 3 Age-specific incidence rates of female invasive breast cancer among non-Hispanic white women in Marin County.
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bias may be present in the incidence rates until the 2010
Census is conducted.
This study was not able to include a range of potentially
confounding risk factors known to play a role in breast
cancer incidence rates, as comprehensive risk factor
information in the study population were not available at
the time of publication. We presented this ecologic, retro-
spective analysis of breast cancer incidence in relation to
hormone therapy use, similar to other published reports
[4,6,8,15] which assessed changes in EPHT use after pub-
lication of the WHI results. Additional risk factors and
their relationship to breast cancer incidence will be the
subject of future reports, although current nationwide
trends in BMI (increasing), parity (decreasing), and late
childbearing (increasing) should tend to increase breast
cancer rates if those trends are mirrored in Marin
County . W e believe it is unlikely that family history of
breast cancer changed significantly during this time
period to impact breast cancer rates.
Although Marin County is a unique population in
terms of education and income, Marin has been a bell-
wether for cancer trends in the past. In the late 1970's
Marin's uterine cancer rates spiked precipitously, provid-
ing strong evidence for the potential risks of EHT on the
uterus. Thus, despite its distinctive demographics, the
relationship between etiologic factors and cancer are not
unique to Marin, and are applicable to women across the
world. Studying populations with extreme risk factor
prevalences can help to signal risk that may be more diffi-
cult to study in populations with more moderate preva-
lence. While the proportion of women using EPHT may
not have dipped as low in other populations as it has in
Marin County, it has decreased as have breast cancer
rates, so the trends and underlying relationship are not
unique to Marin County.
In t his st udy we were a ble t o e xamine br east cancer
incidence and the pattern of HT utilization and cessation
during a period of dramatically altered views on the
health benefits of HT. The extent to which women quit
using EPHT and the lower adoption of EPHT in the years
following the publication of the HERS and WHI study
results is consistent with other reports from elsewhere in
California and the US, as was the subsequent decline in
breast cancer incidence, particularly ER+ breast cancers,
and the estimated proportions of Marin County breast
cancers attributable to current EPHT use. Future studies
addressing the predictors of HT utilization in the post-
WHI era will enhance these results by determining which
populations are most affected by this changing behavior,
and will therefore be most likely to experience changes in
breast cancer incidence. Continued attention to popula-
tion-based patterns of HT utilization and breast cancer
incidence will reveal whether the HERS and WHI trials
resulted in a sustained, long-term reduction in the inci-
dence of HT-related breast cancers.
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